With Merck’s two COVID-19 vaccines falling short of the mark, the U.S. pharma is shifting its focus to late-stage readouts this half for therapeutics to treat the coronavirus. Merck & Co. Inc. (NYSE:MRK) said Monday...

U.S. secures an additional 100M doses of Pfizer-BioNTech vaccinePfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) entered an agreement to supply the U.S. government with an additional 100 million doses of BNT162b2 for $1.95 billion, bringing...

OncoImmune’s move to repurpose its GvHD program for COVID-19 has paid off via a takeout by Merck for $425 million up front. Under the deal, which includes undisclosed milestones and royalties, Merck & Co. Inc....

OncoImmune raises $56M series BOncoImmune Inc. raised $56 million in a series B round co-led by HM Capital and an undisclosed investor. Also participating were fellow new investors GBA Fund and GF Xinde, and existing...

Propelled by growing understanding of their biology, and an expression pattern that goes well beyond T cells, SIGLEC proteins are rising as the next set of checkpoint targets to challenge PD-1. The sugar-binding proteins could...

OncoImmune Inc. (Rockville, Md.) said it raised $15 million in a series A round led by 3E Bioventures Capital. The company's lead candidate, CD24Fc , is in a Phase II study to prevent graft versus host...

OncoImmune raised $15 million in a series A round led by 3E Bioventures Capital. OncoImmune Inc. , Rockville, Md. Alex Himes OncoImmune Inc....

OncoImmune granted Pfizer an exclusive option to license rights to ONC-392 , a preclinical mAb against cytotoxic T-lymphocyte associated protein 4 ( CTLA4 ; CD152 ), and additional anti-CTLA4 antibodies. OncoImmune is eligible to receive up to...

OncoImmune Inc. (Rockville, Md.) granted Pfizer Inc. (NYSE:PFE) an exclusive option to license rights to ONC-392, a preclinical cytotoxic T-lymphocyte associated protein 4 ( CTLA4 ; CD152 ) inhibitor. OncoImmune is eligible to receive $250 million in...

Researchers published in the Proceedings of the National Academy of Sciences that a particular polymorphism of CD24 is associated with a >2 fold increase in the relative risk of MS in the general population (p=0.023)....